Tag: Mental health advocate

  • Mental Illness Is Real. Not Everything Painful Is

    Mental Illness Is Real. Not Everything Painful Is

    On the two opposite ways psychiatry harms patients, and the discipline to know the difference.

    There are two dangerous ways to talk about mental illness, and most public conversation manages to do both at once.

    The first is to deny that it exists.

    The second is to see it everywhere.

    Both are wrong. Both are harmful. Both leave patients worse off.

    On one side are the people who claim psychiatric disease isn’t real, that we’re medicating normal emotion, that diagnosis is social construction, that psychiatry exists to enrich pharmaceutical companies and serve as gatekeepers for a coercive system.

    This is the most extreme antipsychiatry position. And anyone who has actually worked with the seriously mentally ill knows how detached from reality it is.

    Anyone who has sat with a patient in the middle of a manic episode, watched schizophrenia consume a young person’s future, or cared for a loved one whose personality and functioning were permanently altered by illness knows that serious mental illness is not a metaphor. It is not a branding problem. It is not a failure of social acceptance.

    It is real.

    It destroys lives.

    It fractures families.

    It changes the trajectory of everyone around it.

    To deny that is not compassionate. It is cruel.

    But there is a subtler version of denial, one that doesn’t reject psychiatric illness outright, but explains nearly everything through the lens of trauma.

    I don’t mean trauma in the strict PTSD sense. Not the defined clinical syndrome with intrusive memories, avoidance, negative alterations in mood and cognition, and hyperarousal. I mean the broader cultural reflex to frame almost every form of suffering, dysregulation, or dysfunction as “trauma.”

    Trauma matters. Adverse experiences shape brain development, attachment, emotional regulation, interpersonal functioning, substance use, and psychiatric vulnerability. Trauma-informed care has improved medicine, especially by reminding clinicians not to mistake survival strategies for character flaws.

    But trauma does not explain everything.

    It does not explain every case of bipolar disorder. It does not explain every case of schizophrenia. It does not explain every recurrent psychotic episode, every manic state, every severe melancholic depression, or every disabling case of OCD.

    Sometimes the illness is the illness.

    Sometimes the problem is not that society failed to understand a person’s pain. Sometimes the problem is that a devastating psychiatric disease has emerged, and without treatment, it will keep dismantling that person’s life.

    But the opposite error is just as common, and at least as harmful.

    Some clinicians see mental illness in everything.

    They accept every DSM category as if it were a blood test result. They are not critical enough of psychiatry’s limitations. They recognize suffering, and because they want to help, they reach for diagnosis. They reach for medication. They reach for neuromodulation. They reach for a treatment plan that looks medical, billable, and actionable.

    But not every form of suffering is a psychiatric disease.

    Some suffering is grief.

    Some suffering is loneliness.

    Some suffering is moral injury.

    Some suffering is poverty.

    Some suffering is addiction, family chaos, social collapse, lack of purpose, bad relationships, unemployment, burnout, or the consequences of repeated poor decisions.

    Some suffering is just the pain of being human in a world that doesn’t give people much room to fall apart.

    That doesn’t make it fake. It doesn’t mean the person doesn’t deserve help.

    It means the help they need may not live inside a pill bottle.

    This is one of the hardest conversations in psychiatry.

    A patient is suffering. Their family is desperate. Everyone wants the problem named. Everyone wants the plan, the timeline, the medication, the diagnosis, the insurance code, the discharge plan, the promise that things will get better quickly.

    But sometimes the honest answer is:

    “I believe you are suffering. I believe you need help. But I am not convinced that what you have is best understood as a medication-responsive psychiatric disease.”

    That is not abandonment. That is clinical honesty.

    And it is much harder than simply prescribing something.

    The pressure to diagnose is everywhere.

    Families want answers. Hospitals need billable codes. Insurance companies require DSM or ICD diagnoses. Patients often arrive already convinced that if their suffering is severe enough, it must be a disorder. Clinicians are trained inside systems where diagnosis drives reimbursement, treatment authorization, length of stay, documentation, and discharge planning.

    The incentives quietly push us toward overdiagnosis.

    Not always because clinicians are careless. Often because that is simply how the system works.

    A person presents in crisis. They are admitted to an inpatient psychiatric unit. The system expects a psychiatric diagnosis. But not everything that gets someone admitted to inpatient psychiatry is caused by a primary psychiatric disease.

    Sometimes it is. Absolutely. Sometimes it is mania, psychosis, melancholic depression, catatonia, severe OCD, or a lethal depressive episode.

    Those cases need aggressive, evidence-based psychiatric treatment. Medication can be lifesaving. ECT can be lifesaving. Lithium, clozapine, antipsychotics, long-acting injectables, lifesaving. We should never minimize that. Untreated serious mental illness can destroy the patient’s life and the family’s along with it.

    But other times the picture is far more complicated. There may be interpersonal chaos, substance use, housing instability, personality structure, trauma history, family conflict, legal problems, financial collapse, social isolation, or a profound absence of coping skills. The person is suffering, but the suffering does not map cleanly onto a discrete psychiatric disease.

    These patients often respond poorly to medication, because medication was never the main answer.

    Then, when the medication doesn’t work, everyone assumes the psychiatrist chose the wrong one.

    Try another SSRI. Add an antipsychotic. Add a mood stabilizer. Try ketamine. Try TMS. Try something stronger.

    But sometimes the problem isn’t treatment resistance.

    Sometimes the problem is diagnostic overreach.

    This is where psychiatry must be honest with itself.

    We can harm people in two opposite directions.

    We can harm them by failing to diagnose and treat real mental illness.

    We can harm them by diagnosing and treating something as mental illness when it isn’t.

    The first error leaves people untreated and at the mercy of their disease.

    The second exposes people to unnecessary treatment, side effects, identity shifts, stigma, financial cost, and the disappointment that follows when a promised medical solution fails to deliver.

    And when people are harmed by treatments they didn’t need, they often become psychiatry’s loudest critics.

    Not because they were always antipsychiatry.

    Because psychiatry overpromised. Because someone gave them a diagnosis that didn’t fit. Because someone medicalized their suffering without understanding their life.

    Psychiatry does not need to choose between naïve biological reductionism and total diagnostic nihilism. We need a more disciplined middle.

    When there is a clear psychiatric illness, recognizable course, symptom pattern, family history, severity, treatment-responsive biology, we should treat it seriously and decisively. No apologies. No hesitation. No pretending that schizophrenia is just “difference,” or mania is “spiritual awakening,” or severe depression is “sadness,” or OCD is “perfectionism.”

    But when the presentation is questionable, when the course doesn’t fit, when the diagnosis is being stretched to justify intervention, when the suffering is real but not clearly disease-based, we should slow down.

    We should listen longer. Widen the frame. Ask whether medication is likely to help. Consider psychotherapy, structure, sleep, substance use treatment, social repair, family boundaries, vocational support, lifestyle change, and time.

    We should be willing to say:

    “This is real suffering. But I am not going to pretend that a psychiatric label explains all of it.”

    That isn’t minimizing. That’s precision.

    The future of psychiatry depends on our ability to hold both truths at the same time.

    Mental illness is real.

    And not everything painful is mental illness.

    Some people desperately need psychiatric treatment and will be devastated without it. Others need compassion, structure, therapy, accountability, community, and support, but not a diagnosis that follows them for life, or medications that may do more harm than good.

    The goal is not to diagnose less. The goal is to diagnose better.

    The goal is not to medicate everyone. The goal is to treat the right condition, in the right person, at the right time, for the right reason.

    That is the psychiatry I believe in.

    Not psychiatry as social control.

    Not psychiatry as a pill for every problem.

    Psychiatry as a serious medical discipline, one that recognizes disease reality, respects human suffering, and has the humility to know the difference.

  • We say we care about mental health in America

    We say we care about mental health in America

    We say we care about mental health in America.
    But the data—and my front-line experience—say otherwise.

    We are overmedicating, underfunding, and pathologizing poverty, trauma, and stress.
    Instead of addressing why people are sick, we throw pills at symptoms.

    🧠 In my latest article for Psychiatric Times, I make the case that we’ve built a system that profits off disease—not health.
    We’re not solving the problem. We’re institutionalizing it.

    If we want to make America healthy again, we need to stop doing the wrong things.

    👉 Read the full piece here: https://www.psychiatrictimes.com/view/if-we-want-to-make-america-healthy-again-we-are-doing-the-wrong-thing

  • Brexpiprazole + Sertraline: A New Hope for PTSD Treatment

    Brexpiprazole + Sertraline: A New Hope for PTSD Treatment

    We’ve all seen it: PTSD that won’t budge. Patients try sertraline or paroxetine—the so-called “gold standards”—and walk away with little more than side effects and a sense of failure.

    Enter a new contender: brexpiprazole + sertraline.

    A recent Phase 3 randomized controlled trial might finally offer something real for those stuck in the PTSD trenches.

    🚨 The Results

    In a study across 86 sites with over 550 adults, adding brexpiprazole (2–3 mg) to sertraline (150 mg) led to a 5.6-point greater reduction on the CAPS‑5 (the gold-standard PTSD measure) compared to sertraline + placebo. That’s not a marginal win—it’s a clinically significant shift, especially in a treatment-resistant population.

    Responder rates tell the story even clearer:

    • 68.5% of patients on the combo had ≥30% reduction in symptoms
    • Compared to 48.2% on sertraline alone
    • That’s a +20% absolute response rate boost

    And the improvements weren’t just short-lived. Benefits held through 12 weeks, even during a post-treatment observation period. No relapse, no rebound—just stability.

    🧩 More Than Symptom Checklists

    It wasn’t just about PTSD symptoms. This combo also:

    • Improved psychosocial functioning (B-IPF scores)
    • Reduced anxiety and depression (HADS)
    • Lowered global illness severity (CGI-S)
    • Helped with all symptom clusters, including reexperiencing, avoidance, and hyperarousal

    That’s rare. Most meds in psychiatry hit one or two domains and leave the rest hanging. This one made a dent where it counts: function, resilience, and real-world relief.

    ⚠️ What About Side Effects?

    Brexpiprazole is still an atypical antipsychotic, so there’s baggage. But the trial data suggest it’s relatively well-tolerated:

    • Fatigue: 6.8%
    • Weight gain: 5.9%
    • Somnolence: 5.4%
    • Discontinuation due to AEs? Just 3.9%, vs 10.2% in placebo.

    No new safety signals. No psychosis worsening. Not perfect, but not the metabolic disaster zone we see with other agents.

    🚀 What’s Next?

    The FDA is reviewing this combo

    For those of us treating chronic PTSD, this may be a real tool—not just a shiny new molecule with good marketing.

    Until then, it’s worth paying attention. Because when sertraline alone doesn’t cut it—and we know it often doesn’t—this combo could offer a lifeline.

  • 🧠 Blog Post: The Dark Mirror—How Screen Time Drains Our Mental Health

    🧠 Blog Post: The Dark Mirror—How Screen Time Drains Our Mental Health

    It’s no secret that screen time affects our mental health—but we still underestimate just how deeply it cuts.

    As a psychiatrist, I find myself glued to my phone far more than I’d like. I’m not scrolling TikTok—I’m answering emails, responding to messages, and compulsively checking patient updates. Yet, even in this “productive” digital use, I feel drained. The compulsion to keep checking leaves me feeling hollow and anxious.

    Now imagine that same digital pull in the hands of a developing mind.

    A recent study in JAMA examined over 4285 adolescents and found a clear link: teens with high levels of addictive digital media use were significantly more likely to report depression, anxiety, and suicidal thoughts.

    The connection isn’t surprising. Much of what’s consumed online isn’t educational or uplifting—it’s filtered perfection, highlight reels, and influencer fantasy. The more time spent scrolling, the easier it is to feel like you’re falling behind in life, socially or emotionally.

    It’s telling that Steve Jobs famously limited his own children’s access to screens, despite pioneering the very technology we now feel chained to.

    This isn’t about demonizing devices—it’s about reclaiming our attention and protecting mental space, especially for young people.

    We need digital hygiene just like we need physical hygiene. That means:

    • Setting screen-time boundaries
    • Promoting offline connection
    • Reframing how we compare ourselves to curated content

    Mental health isn’t just shaped in the therapy room—it’s shaped by the world we scroll through every day.

  • Understanding Psychiatry: Science vs. Skepticism

    Understanding Psychiatry: Science vs. Skepticism

    🧠 “Psychiatry is a scam.” “Big Pharma controls your brain.” “Mental illness isn’t real.”

    You’ve heard the takes. Now here’s the truth.

    In my new article for Psychiatric Times, I dive headfirst into the controversy:
    👉 Understanding Psychiatry: Navigating Skepticism and Science
    https://www.psychiatrictimes.com/view/understanding-psychiatry-navigating-skepticism-and-science

    I don’t dodge the hard questions—about overmedication, broken trust, and bad science—but I also push back against lazy anti-psychiatry takes that ignore the very real suffering of patients.

    If you care about the future of mental health care, this one’s worth your time.

  • Mirtazapine: A unique tool in the antidepressant toolbox

    Mirtazapine isn’t your typical SSRI—and that’s exactly why it can be useful in the right context.

    ✅ When to consider mirtazapine:

    • Depression with insomnia
    • Poor appetite or weight loss
    • Concern about sexual side effects
    • Patients struggling with GI intolerance to SSRIs

    ⚠️ When to avoid it:

    • Obesity or metabolic syndrome
    • Risk of daytime sedation
    • Orthostatic hypotension history

    Mechanistically, it’s a noradrenergic and specific serotonergic antidepressant (NaSSA). It works via alpha-2 autoreceptor blockade, enhancing 5-HT1A transmission while avoiding 5-HT2/3 activity—translating to fewer GI and sexual side effects.

    💡 Pro tip:
    Sedation is dose-dependent and paradoxical:
    Lower doses (7.5–15 mg) = more sedation
    Higher doses (30–45 mg) = less sedation

    In short, mirtazapine shines in cases where sleep, appetite, or tolerability limit other antidepressants—but use it strategically.

  • Reject dogma—embrace nuance in Psychiatry

    🔹 Psychoanalysis should not be treated as sacred doctrine. Freud was a clever and influential thinker, but not a prophet.


    🔹 Biological psychiatry is equally vulnerable to dogma. Not every symptom signals a disease, and not every distress warrants medication.


    🔹 That said, evidence-based pharmacology has its place—especially when medications show clear, replicable benefits in defined clinical conditions.

    The future of psychiatry lies in balanced thinking, not blind allegiance—to Freud, to biology, or to any single model of mind.

  • Understanding Social Anxiety Disorder: Key Insights and Treatments

    Understanding Social Anxiety Disorder: Key Insights and Treatments

    What if your biggest fear was simply being seen?
    For millions living with Social Anxiety Disorder (SAD), everyday interactions—like answering a question in class or speaking up at work—can feel terrifying. Despite being one of the most prevalent and impairing anxiety conditions, SAD remains widely under-recognized.

    📊 Up to 8.4% of people meet criteria for SAD in a given year, yet only 20–40% recover after 20 years without treatment (Ruscio et al., 2008). Median age of onset? Just 13 years old.

    👤 Case Vignette: When Fear Takes Over

    At 15, “Jenna” stopped raising her hand in class—not because she didn’t know the answers, but because she was terrified of being laughed at. By college, she avoided presentations, skipped networking events, and turned down internships. Her friends thought she was shy. One professor suggested depression. But underneath was a paralyzing fear of judgment: classic Social Anxiety Disorder.

    🤝 What Is Social Anxiety Disorder?

    SAD is more than introversion or shyness. It’s a persistent, intense fear of being judged, embarrassed, or negatively evaluated in social or performance situations. This fear leads to avoidance behaviors that impair social, academic, and occupational functioning.

    ⚠️ Why Is It So Often Missed?

    SAD is frequently overshadowed by overlapping symptoms seen in:

    • Major Depressive Disorder (social withdrawal, low self-esteem)
    • Generalized Anxiety Disorder (excessive worry)
    • Avoidant Personality Disorder (longstanding social inhibition)
    • Body Dysmorphic Disorder (fear of negative evaluation tied to appearance)

    Because of this diagnostic overlap, many individuals go undiagnosed—or misdiagnosed—for years.

    🧠 Clinical Considerations

    1. SAD Is Not “Just Shyness”

    Shyness is a personality trait; SAD is a clinical condition. The difference lies in impairment: SAD interferes with daily life, relationships, academic goals, and career opportunities.

    2. Early Onset, Long Course

    Most individuals report symptoms starting in early adolescence. Without intervention, SAD often persists into adulthood and increases the risk of depressionsubstance use, and functional disability.

    3. Functional Impairment Is Significant

    SAD can lead to:

    • Academic underachievement
    • Avoidance of job interviews or public speaking
    • Social isolation
    • Delayed life milestones (e.g., dating, career advancement)

    4. Evidence-Based Treatments Exist

    🧠 Cognitive Behavioral Therapy (CBT):

    • Gold-standard psychotherapy
    • Targets negative thought patterns and avoidance behaviors
    • Often includes exposure exercises to feared situations
    • Group CBT is especially effective for SAD

    💊 Pharmacologic Options:

    • First-line: SSRIs (e.g., sertraline, paroxetine)
    • SNRIs: Like venlafaxine, also effective
    • Beta-blockers: May help with performance-only SAD (e.g., public speaking)
    • BenzodiazepinesNot recommended due to dependence risks and avoidance reinforcement

    🔄 Combined Therapy

    Some individuals benefit most from CBT + medication, particularly those with moderate-to-severe or treatment-resistant symptoms.

    📣 Call to Action

    Too many individuals live in silence with Social Anxiety Disorder. If you or someone you know avoids social situations due to fear of judgment, don’t ignore it. SAD is real. It’s common. And—most importantly—it’s treatable.

    👉 Talk to a mental health professional
    👉 Share this post to raise awareness
    👉 Start the conversation

  • 📉 Overdose Deaths in the U.S. Dropped Nearly 27% in 2024 – A Sign of Hope 🇺🇸

    📉 Overdose Deaths in the U.S. Dropped Nearly 27% in 2024 – A Sign of Hope 🇺🇸

    📉 Overdose Deaths in the U.S. Dropped Nearly 27% in 2024 – A Sign of Hope 🇺🇸

    According to newly released CDC data, the U.S. experienced a nearly 27% decline in overdose deaths last year — the first major drop in over five years. While the crisis is far from over, this marks a critical turning point and a reason for cautious optimism.

    Key contributors to this progress include:

    ✅ Expansion of harm reduction strategies

    ✅ Increased access to naloxone and medications for opioid use disorder

    ✅ Shifts in drug supply dynamics and targeted public health interventions

    As someone on the front lines caring for patients every day, I’ve witnessed firsthand the devastating toll of opioid addiction. I’ve lost patients to this crisis — and I’ve also seen close friends and family fight their way back from the brink. Their recovery wouldn’t have been possible without access to critical resources, especially life-saving medications and sustained support.

    This progress didn’t happen by chance — it’s the result of continued investment in prevention, treatment, and recovery. We cannot afford to lose momentum now. If anything, this is the moment to double down.

    Let’s keep the pressure on. Reach out to your representatives. Push for increased funding. Our collective commitment has brought us this far — now let’s go even further. Lives depend on it.

    Let’s build on this progress with compassion, science, and unwavering commitment.

  • Avoid Tianeptine: FDA Alerts Consumers to Risks

    Avoid Tianeptine: FDA Alerts Consumers to Risks

    The U.S. Food and Drug Administration (FDA) has issued a critical health warning about the growing availability of tianeptine, a dangerous, unapproved substance being sold as a dietary supplement under names like Zaza, Tianna Red, Pegasus, and others.

    Commonly referred to as “gas station heroin”, tianeptine mimics opioid-like effects and is being sold in convenience stores, gas stations, smoke shops, and online—posing serious health risks to the public.

    ⚠️ Why This Matters:

    Tianeptine is not approved for any medical use in the U.S. Despite this, it is widely marketed for supposed benefits like mood enhancement, anxiety relief, or cognitive boost. These claims are not supported by clinical evidence, and the risks are significant.

    🩺 Serious Health Risks Associated With Tianeptine:

    ⚠️ Death, particularly when combined with alcohol or other substances

    ⚠️ Respiratory depression (slow or stopped breathing)

    ⚠️ Seizures

    ⚠️ Loss of consciousness

    ⚠️ Confusion and agitation

    ⚠️ Opioid-like withdrawal symptoms

    🛑 What You Can Do:

    Report adverse reactions to the FDA via MedWatch: https://www.fda.gov/medwatch

    Avoid any products labeled as containing tianeptine.

    Do not trust unregulated supplements marketed for mental clarity or energy.

    📌 Quick Summary:

    • Tianeptine = dangerous, unapproved opioid-like drug
    • Sold as a supplement under names like Zaza or Tianna Red
    • Linked to seizures, coma, and death
    • Avoid these products and warn others
    • Report side effects to the FDA MedWatch Program